296 related articles for article (PubMed ID: 20537791)
1. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
[TBL] [Abstract][Full Text] [Related]
2. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model.
Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M
Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918
[TBL] [Abstract][Full Text] [Related]
4. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
Guo BL; Liu Z; Aldrich WA; Lopez RD
Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
6. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
10. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells.
Nakajima J; Murakawa T; Fukami T; Goto S; Kaneko T; Yoshida Y; Takamoto S; Kakimi K
Eur J Cardiothorac Surg; 2010 May; 37(5):1191-7. PubMed ID: 20137969
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
13. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
14. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
15. Modulation of innate immunity by IL-18.
Li W; Yamamoto H; Kubo S; Okamura H
J Reprod Immunol; 2009 Dec; 83(1-2):101-5. PubMed ID: 19853308
[TBL] [Abstract][Full Text] [Related]
16. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
[TBL] [Abstract][Full Text] [Related]
17. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
[TBL] [Abstract][Full Text] [Related]
18. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
[TBL] [Abstract][Full Text] [Related]
19. gammadelta T cells: a new frontier for immunotherapy?
Lamb LS; Lopez RD
Biol Blood Marrow Transplant; 2005 Mar; 11(3):161-8. PubMed ID: 15744234
[TBL] [Abstract][Full Text] [Related]
20. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
Liu Z; Fan H; Wu Y; Chen B
Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]